TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Family Nurture Intervention in the CHoNJ NICU

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Infant is between 26/0 and 32/6 weeks gestational age upon admission for the INTERVENTION / STANDARD care group OR 38-42 weeks for the FULL TERM group~* Infant's weight is appropriate for gestational age (AGA)~* Infant is a singleton~* Mother is 18 years of age or older~* Mother has at least one supporting person in the home (e.g. significant other, mother, father, sibling, aunt, grandmother, step-parent) (not applicable for FULL TERM group)~Exclusion Criteria:~* Infant's attending does not recommend enrollment in study~* The infant has severe congenital anomalies, including chromosomal anomalies or an Intraventricular Hemorrhage (IVH) Grades 3 and 4~* Mother has known history of substance abuse, severe psychiatric illness or psychosis~* Status of enrolled subject changes and subject no longer falls in inclusion criteria~* Mother and/or infant has a medical condition that precludes intervention components~* Mother and/or infant has a contagion that endangers other participants in the study~* Mother-Infant dyad receives less than one week of intervention (not applicable to the FULL TERM group)

- Gender: ALL
- Minimum Age: 26 Weeks
- Maximum Age: 42 Weeks
- Healthy Volunteers: f

Study Arms:
- Standard Care (Type: NO_INTERVENTION): Mothers are given infant care instruction as part of standard care
- Facilitated infant care (Type: EXPERIMENTAL): Family Nurture Intervention
- Full Term EEG (Type: OTHER): Small group of healthy, Full-Term infants will receive two sleep EEGs (one in unit, and one 4 weeks post discharge) for healthy control comparison to preterm infants

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Celiac Plexus Block for Chronic Pancreatitis RCT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Presentation with upper abdominal pain suggestive of pancreatitis who are undergoing EUS for evaluation~* M ANNHEIM severity index of 6 or greater to be included~* Intermittent episodes of pain\>3 requiring opiate medication~Exclusion Criteria:~* Patients who have allergic reactions to steroids or bupivacaine~* INR \>1.6~* platelets \<75~* decompensated cirrhosis~* incarcerated~* \<18 years old~* unable to give informed consent~* peptic ulcer disease~* ongoing substance or alcohol use

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- EUS with Celiac Block (Type: EXPERIMENTAL): Celiac Block with triamcinolone and bupivicaine Intra Plexus Triamcinolone and Bupivicaine Injection
- EUS without Celiac Block (Type: ACTIVE_COMPARATOR): Patients will undergo EUS but no celiac block will be performed

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Early and Short Psycho-educational Lifestyle Intervention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Hospitalized patients in one of four adult psychiatric units of eastern pole of the Hospital Vinatier~* man or woman~* aged between 18 (major) and 45 years (age limit on inducing a cardiovascular risk)~* receiving anti-psychotic medication or antiepileptic mood stabilizer introduced during this hospitalization: patients must be treatment-naive or already under psychotropic drug(s) since less than 10 years~Exclusion Criteria:~* minor~* aged over 45 years at inclusion~* pregnancy or breastfeeding~* patient suffering from a neurodegenerative disease~* patient suffering from an eating disorder~* patient with a BMI\> 30~* patient treated for more than 10 years by anti-psychotic medication or antiepileptic mood stabilizer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Motivational group (Type: EXPERIMENTAL): psycho-education program inspired by motivational interviewing and behavioral psychotherapy
- educational group (Type: ACTIVE_COMPARATOR): exclusively informative psycho-education program

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study Testing if Medicine Can Make Pigment Epithelium Detachments Regress and Stabilize the Vision in Eyes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ability to provide written informed consent and comply with study assessments for the full duration of the study~* Age \> 50 years~* Pigment epithelium detachment in an eye not earlier treated with anti-VEGF or verteporfin PDT.~* ETDRS Best Corrected Visual acuity 20/32 - 20/400~Exclusion Criteria:~* Prior treatment with verteporfin, or external-beam radiation therapy, or transpupillary thermotherapy, Previous subfoveal focal laser photocoagulation involving the foveal center, History of vitrectomy, submacular surgery, or other surgical intervention for AMD.~* CNV, Subfoveal fibrosis or atrophy in study eye.~* Concurrent eye disease in the study eye that could compromise visual acuity (e.g., diabetic retinopathy, advanced glaucoma) or require medical or surgical intervention during the study. Active intraocular inflammation in the study eye.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): aflibercept intravitreal injections, 2.0 mg monthly x 3 doses, then injections as needed based on recurrence of activity on OCT. If no effect of the treatment; aflibercept intravitreal injections, 2.0 mg x 3 doses is repeated, then injections as needed based on recurrence of activity on OCT. If no effect of the treatment; verteporfin photo dynamic therapy.
- Observation (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Effects of PAP Treatment of OSA in Patients With Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 and \< 75 years of age.~* Apnea-hypopnea index (AHI) of at least 15/hr based on overnight polysomnography.~* New York Heart Association Class 3 or less.~* LV ejection fraction \<45% based on a prior imaging study (as measured within one year of baseline studies).~* Absence of exacerbation of heart failure requiring hospitalization within the previous 3 mos.~* Optimal pharmacologic therapy at the highest tolerated dose \[3\].~Exclusion Criteria:~* Use of anti-diabetic medications~* Primary valvular heart disease~* Unstable angina~* Myocardial infarction, cardiac surgery, or revascularization procedure within the previous 3 months~* Uncontrolled hypertension defined as systolic blood pressure \>160 mm Hg or diastolic blood pressure \>100 mm Hg.~* Active smoking (Patient should not have smoked for at least 1 month prior to baseline studies and has the intention not to smoke for the duration of the study period)~* Use of illicit drugs~* Current use of home oxygen therapy~* Requirement for a bi-level machine to treat sleep apnea~* Use of corticosteroids~* Creatinine clearance \< 30ml/min (calculated from serum creatinine)~* Pregnant women will be excluded as pregnancy interferes with glucose and adiponectin. Additionally the contrast used in the cardiac MRIs may be harmful to unborn babies. Females of child bearing potential must agree to use effective contraception during the trial.~* Any contraindication to CMR (Cardiovascular magnetic resonance) imaging such as ferromagnetic foreign body, orbital metal, cerebral aneurysm clip, pacemaker, defibrillator, neurostimulator, allergy to gadolinium-based contrast, or severe claustrophobia. The standard FDA and OSUMC's screening guidelines for MRI safety will be followed.~* Inability or unwillingness to provide consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- CPAP Arm (Type: ACTIVE_COMPARATOR): Receive effective CPAP treatment for one month
- Control Arm (Type: NO_INTERVENTION): Receive no treatment for one month

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Excimer Laser Phototherapy Outcomes in the Treatment of Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of chronic plaque psoriasis for at least 6 months~2. Age ≥ 18 years~3. Body surface area affected ≤ 10 percent~4. Presence of at least one pair of bilateral target lesions with an area of at least 20 cm2 per target lesion. The bilateral target lesions must be present in the same category of anatomical region (e.g., bilateral lower extremities, bilateral upper extremities or bilateral trunk).~Exclusion Criteria:~1. active or past history of erythrodermic psoriasis, guttate psoriasis, or pustular psoriasis~2. history of photosensitivity disorder~3. history of malignant melanoma~4. active, invasive non-melanoma skin carcinoma~5. Fitzpatrick Skin Type I~6. Subject has received ultraviolet B phototherapy or any topical anti-psoriatic therapy within two weeks prior to starting the study.~7. Subject has received systemic or topical psoralen-ultraviolet A photochemotherapy within four weeks prior to starting the study.~8. Subject has received biologic therapy within three months of starting the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Conventional Dosing (Type: ACTIVE_COMPARATOR): Patients psoriasis to be treated with Excimer laser phototherapy based on conventional dosing guidelines. These guidelines determine the starting dose based on plaque thickness and the skin type of the patient. Patients will also be evaluated for psoriasis plaque response to test doses. The best dose will be selected from a test matrix of doses.
- Plaque based dosing (Type: EXPERIMENTAL): Patients will also be evaluated for psoriasis plaque response to test doses. The best dose will be selected from a test matrix of doses.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: SWOG-9507, Fenretinide in Treating Patients With Neoplasia of the Mouth

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically proven oral mucosal intraepithelial neoplasia Stage II: moderate dysplasia, keratosis with atypia Stage III: severe keratinizing or nonkeratinizing dysplasia No myelodysplastic syndrome No retinopathies~PATIENT CHARACTERISTICS: See General Eligibility Criteria~PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent biologic therapy Chemotherapy: No concurrent chemotherapy Endocrine therapy: No concurrent endocrine therapy Radiotherapy: No concurrent radiotherapy Surgery: Prior surgical ablation of prior dysplastic sites allowed Other: At least 2 months since prior therapy toxicities Patient Characteristics-- Age: Not specified Performance Status: SWOG 0-1 Life Expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception at least 1 month before, during, and at least 2 months after study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- treatment (Type: EXPERIMENTAL): Fenretinide 200 mg PO days 1-25, q 28 days x 6 cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: World Health Organization Disability Assessment Schedule (WHODAS-II) for Patients With Symptomatic Lumbar Disc Herniation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients seen for symptomatic lumbar disc herniation~* Radiated pain concordant with nerve root~* With or without motor restriction~* Able to read and write~* Signed the informed consent form~Exclusion Criteria:~* Central nervous system pathology (with or without treatment)~* Diagnosis of rheumatic inflammatory disease or fibromyalgia~* Red flags for underlying systemic disease~* Criteria for diagnosis of symptomatic spinal stenosis~* Symptoms suggesting saddle anesthesia, cauda equina, loss of sphincter tone or paraparesis~* Motor deficit that progresses or does not improve in 6 weeks

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: OTHER): Measurement characteristics of WHODAS II (World Health Organization Disability Assessment Schedule)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Analysis of Osteoimmune Interactions Linking Inflammation and Bone Destruction in Aggressive Periodontitis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
* Inclusion criterias for agressive periodontits~  * Young patients not suffering of any médical conditions~ * Small amount of calculus detected~ * Pocket depth \>5mm~ * Alveolar Bone loss \>50%~* Inclusion criterias for chronic periodontitis~  * Evident presence of calculus above or under the gingiva~ * Pocket depth \>5mm~* Inclusion criterias for control patients :~  * Young patients in need of impacted wisdom teeth removal~ * And not suffering of chronic or agressive periodontitis~* Exclusion criterias :~  * Patients with blood disorder~ * Patients presenting with liver, kidney, or vascular disorder, and /or psychiatric disorder~ * Patients who have allergies~ * Patients taking biphosphonates, anticoagulant drugs, or anticonvulsivant~ * Patients who have had a cancer of the mouth, and/or treated by radiotherapy~ * Patients who have taken anti-inflammatory drugs, and/or anti-cancer drugs, and/or immuno-suppresive drugs in the past 6 months~ * Patients who have had a periodontal treatment in the past 12 months~ * Pregnant Women~ * Patients juged difficult to follow by the investigator~ * Vulnerable patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- chronic periodontitis (Type: OTHER): biopsy of periodontal granulation tissue (surgical waste)
- aggressive periodontitis (AP) (Type: OTHER): biopsy of periodontal granulation tissue (surgical waste)
- controls (Type: OTHER): necessitating an extraction of wisdom teeth

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: CoSeal in Liver and Biliary Surgery in Prevention of Denovo Hepatic Adhesion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Major patients.~* Hepatic Carriers of metastases.~* Eligible with a procedure of surgical eradication in two brought closer times (time lower than 3 months).~* Strategy validated in multidisciplinary meeting of cancerology.~* Enlightened Assent given and signed before the intervention.~Exclusion Criteria:~* Anaesthetic Counter-indications with a procedure in two times~* Carcinose péritonéale, reached metastatic not éradicable~* Over-sensitiveness or allergy known to polyethylene CoSeal glycol~* Concomitant Use of another antiblocking agent~* Immunodéprimés Patients or taking drugs immunodépresseurs with the long court like the corticosteroids,~* Impossibility of subjecting itself to the medical monitoring imposed by the study for reasons geographical, social, psychic or medical.~* Concomitant Participation in another clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Group COSEAL (Type: EXPERIMENTAL): None
- Reference group (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Telemedicine in Pregnant Women With Type 1 Diabetes Mellitus

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* type 1 diabetics who are at or less than 16 weeks in their pregnancy~* 18 years of age or more~* Voluntary participation~Exclusion Criteria:~* \<18 years of age~* Not Type I diabetic

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Microbiome and Axial Spondyloarthritis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* ICD-10 disease code or diagnosis for AxSpA~* Confirmed diagnosis of AxSpA, based on ASDAS criteria including both non-radiographic axial spondyloarthritis and ankylosing spondylitis~* HLA-B27 positive~* Signed informed consent prior to any study-specific procedures are performed~* Females and males aged 18 years or older~* Able to read, speak and understand English~* Willing and able to use the at-home collection kits and mail in pre-paid mailers~* Willing and able to use a smartphone app or web app to answer surveys~* Willing and able to make and keep/travel to a local lab visit for blood collection~* Willing and able to follow the study instructions, as described in the recruitment letter~Exclusion Criteria:~* Unable or unwilling to use Viome's App on an iPhone or Android smartphone~* Not HLA-B27 positive~* No diagnosis for AxSpA/AS~* Pregnant or nursing~* Other diagnosis of arthritis (rheumatoid, osteoarthritis, psoriatic arthritis, psoriatic spondyloarthritis)~* IBD/Crohn's disease/ulcerative colitis~* Use of antibiotics or Sulfasalazine within the past 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- All Study Participants (Type: OTHER): Enrolled with: AxSpA diagnosis, HLA-B27 positive, mASDAS \> or = 1.3 and HLA-B27 positive. Will complete surveys online or on an app, about mental and physical health and how they are doing, submits and collection of samples (blood, stool, saliva, urine, fasting blood test at local lab). Receives results of some of the analysis of samples. Participants that qualify and complete the first set of samples can be eligible for the 3 and 6 month longitudinal follow-up collection kits.~All participants receive dietary recommendations based on samples collected and the analysis of the microbiome.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Two Types of Bowel Preparation for Inpatient Colonoscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* 18 years or older~* Be able to comprehend the trial and provide written informed consent in French or English, or a close relative with power of attorney~* Have a recognised indication for full colonoscopy after evaluation by a gastroenterologist or surgeon~* Be hospitalized or in the ED of a participating hospital center.~* Need to receive a bowel preparation during hospitalization or the ED stay.~* Be able to complete the follow-up patient response form in French or English~Exclusion Criteria:~* Patient refusal~* A suspected or diagnosed bowel obstruction~* A toxic megacolon~* Ileus~* Decompensated heart failure~* Severe acute renal failure~* Severe electrolyte imbalance~* Previous bowel preparation in the last 7 days~* Pregnancy~* Time of randomization before 9h00 or after 22h00

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PEG electrolytes 2L/2L split dose (Type: EXPERIMENTAL): None
- Bisacodyl 15 mg and PEG/electrolytes 1L/1L split dose (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues